Psychiatr. pro Praxi, 2008; 9(4): 177-180

Antiepileptic drugs in the treatment of schizophrenia spectrum psychoses

doc. MUDr. Ladislav Hosák Ph.D, prof. MUDr. Jan Libiger CSc
Psychiatrická klinika LF UK a FN Hradec Králové

Antipsychotics are the first-choice treatment in schizophrenia and related psychoses. Because almost 20 per cent of patients do not respond to antipsychotics alone, combination treatment with antiepileptics is a subject of interest. We review the most recent knowledge in this field based on the mechanism of action of individual antiepileptics. High doses of benzodiazepines may be effective in positive symptoms of schizophrenia, anxiety and agitation. Augmentation of antipsychotics with carbamazepine may be beneficial in violent patients, subjects with affective symptoms and EEG abnormalities. Positive symptoms, irritability, hostility and aggressiveness in schizophrenia are reduced by valproate. Evaluation of effect of lamotrigine on a broad spectrum of schizophrenia-like symptoms requires further studies.

Keywords: Klíčová slova: schizofrenie, augmentace, antiepileptika, GABA, glutamát.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hosák L, Libiger J. Antiepileptic drugs in the treatment of schizophrenia spectrum psychoses. Psychiatr. praxi. 2008;9(4):177-180.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatr 2000; 57: 270-276. Go to original source... Go to PubMed...
    2. Basan A, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2004; CD004028. Go to original source...
    3. Brandt C, Fueratsch N, Boehme V, Kramme C, Pieridou M, Villagran A et al. Development of psychosis in patients with epilepsy treated with lamotrigine: Report of six cases and review of the literature. Epilepsy Behav 2007 (in print). Go to original source... Go to PubMed...
    4. Brewerton TD. The phenomenology of psychosis associated with complex partial seizure disorder. Ann Clin Psychiatr 1997; 9: 31-51. Go to original source...
    5. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28: 182-192. Go to original source... Go to PubMed...
    6. Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York state office of mental health. Psychiatr Quarterly 1998; 69: 283-300. Go to original source... Go to PubMed...
    7. Češková E, Tůma I, Přikryl R, Pěč O. Schizofrenie. In: Raboch J a kol. Psychiatrie. Doporučené postupy psychiatrické péče II. Praha: Infopharm 2006: 54-63.
    8. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A, ,glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989; 12: 1-13. Go to original source... Go to PubMed...
    9. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998; 31: 122-125. Go to original source... Go to PubMed...
    10. Dursun SM, McIntosh D. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatr 1999; 56: 950. Go to original source... Go to PubMed...
    11. Gobbi G, Gaudreau PO, Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychopharmacol 2006; 26: 467-473. Go to original source... Go to PubMed...
    12. Hardoy MC, Carta MG, Carpiniello B, Cianchetti C, Congia S, D´Errico I. Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up. J Affect Disord 2003; 75: 125-130. Go to original source... Go to PubMed...
    13. Hesslinger B, Klose P, Normann C, Langosch JM, Berger M, Walden J. Zur adjuvanten Behandlung schizophrener Störungen mit Carbamazepin. Fortschr Neurol Psychiat 1998; 66: 145-150. Go to original source... Go to PubMed...
    14. Hollister LE, Müller-Oerlinghausen B, Rickels K, Shader RI. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; Suppl 1/93: 72S-81S. Go to original source...
    15. Hosák L. Klinický přínos farmakogenetiky v psychiatrii. Psychiat. pro Praxi 2006; 7: 168-170.
    16. Jablonowski K, Margolese HC, Chouinard G. Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Can J Psychiatry 2002; 47: 975-976. Go to original source... Go to PubMed...
    17. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215-228. Go to original source... Go to PubMed...
    18. Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds GP. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1988; 1: 583-584. Go to original source... Go to PubMed...
    19. Koran LM. Gamma-aminobutyric-acid deficiency in schizophrenia. Lancet 1976; 2: 1025. Go to original source... Go to PubMed...
    20. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatr 1994; 51: 199-214. Go to original source... Go to PubMed...
    21. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev 2002; CD001258. Go to original source...
    22. Leweke FM, Gerth CW, Koethe D, Faulhaber J, Klosterkotter J. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry 2004; 161: 1130-1131. Go to original source... Go to PubMed...
    23. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005; 59: 613-615. Go to original source... Go to PubMed...
    24. MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995; Suppl 2/95: S2-S12. Go to original source... Go to PubMed...
    25. Malphrus AD, Wilfong AA. Use of the newer antiepileptic drugs in pediatric epilepsies. Curr Treat Options Neurol 2007; 9: 256-267. Go to original source... Go to PubMed...
    26. Maršálek M. Extrapyramidové polékové poruchy. In: Seifertová D, Praško J, Höschl C. Postupy v léčbě psychických poruch. Praha: Academia Medica Pragensis 2004: 387-406.
    27. McDaniel WW, Spiegel DR, Sahota AK. Topiramate effect in catatonia: a case series. J Neuropsychiatry Clin Neurosci 2006; 18: 234-238. Go to original source... Go to PubMed...
    28. Menzies L, Ooi C, Kamath S, Suckling J, McKenna P, Fletcher P et al. Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 2007; 64: 156-167. Go to original source... Go to PubMed...
    29. Migliardi G, D´Arrigo C, Santoro V, Bruno A, Cortese L, Campolo D et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol 2007; 30: 107-113. Go to original source... Go to PubMed...
    30. Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Int J Clin Psychiatr 1989; 11: 199-207.
    31. Nachshoni T, Levin Y, Levy A, Kritz A, Neumann M. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatr 1994; 35: 22-26. Go to original source... Go to PubMed...
    32. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989; 80: 250-259. Go to original source... Go to PubMed...
    33. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007. Go to original source... Go to PubMed...
    34. Pfeffer G, Chouinard G, Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int Clin Psychopharmacol 2005; 20: 179-181. Go to original source... Go to PubMed...
    35. Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006; CD005962. Go to original source...
    36. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. J Psychiatr Neurosci 1992; 17: 1-14.
    37. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: A comparative review. Bas Clin Pharmacol Toxicol 2007; 100: 4-22. Go to original source... Go to PubMed...
    38. Stone JM, Pilowsky LS. Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets 2007; 6: 265-272. Go to original source... Go to PubMed...
    39. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hivaurinen S, Eronen M et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005; 66: 1012-1015. Go to original source... Go to PubMed...
    40. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2007; CD006391. Go to original source...
    41. Wassef AA, Dott SG, Harris A, Brown A, O´Boyle M, Meyer WJ et al. Critical review of GABAergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999; 19: 222-232. Go to original source... Go to PubMed...
    42. Wassef A, Watson DJ, Morrison P, Bryant S, Flack J. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989; 9: 45-48. Go to original source... Go to PubMed...
    43. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatr 1991; 148: 714-726. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.